Last reviewed · How we verify
Advair Diskus100/50 µg
Advair Diskus combines fluticasone propionate (an inhaled corticosteroid) and salmeterol (a long-acting beta-2 agonist) to reduce airway inflammation and dilate airways in asthma and COPD.
Advair Diskus combines fluticasone propionate (an inhaled corticosteroid) and salmeterol (a long-acting beta-2 agonist) to reduce airway inflammation and dilate airways in asthma and COPD. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Advair Diskus100/50 µg |
|---|---|
| Also known as | fluticasone, salmeterol |
| Sponsor | University of Florida |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate binds to glucocorticoid receptors in the lungs, suppressing inflammatory cytokine production and reducing airway edema and mucus secretion. Salmeterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and prolonging airway patency. Together, these agents provide both anti-inflammatory and bronchodilatory effects for sustained symptom control.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Muscle cramps
- Oral candidiasis
- Dysphonia
Key clinical trials
- BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients (PHASE3)
- Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate (NA)
- Dose-Response of Salmeterol in Children (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Advair Diskus100/50 µg CI brief — competitive landscape report
- Advair Diskus100/50 µg updates RSS · CI watch RSS
- University of Florida portfolio CI